Specialty Pharmacy

Top articles of the week on Specialty Pharmacy Times.

Women older than age 65 face higher risk for several comorbidities from breast cancer treatment.

Recent advances and updates in oncology and cancer drug development.

Skin cells from diabetic foot ulcers could be reprogrammed to acquire properties of embryonic-like cells.

Specialty pharmacies may be able to better monitor comorbid conditions in psoriatic arthritis patients.

Children and adolescents with JIA are also likely to develop other autoimmune diseases beyond diabetes.

Individuals with primary immunodeficiency carry increased risk of developing a variety of cancers.

The drug eCF506 can selectively block the Src tyrosine kinase and stop the growth of breast cancer cells.

Larger waist circumference associated with an increased risk of aggressive prostate cancer.

The CRISPR system may revolutionize the treatment of a range of diseases.

An antibody showed the ability to bind to the protein Bak and cause apoptosis.

New drug class offers hope for lymphomas and leukemia.

Blocking the ERK1/2 pathway and the compensatory ERK5 pathway stopped the growth of colorectal tumors.

The Right to Try Act allows terminally ill patients to take investigational treatments that have passed basic safety testing.

Improving the function neuron activity may effectively treat Rett syndrome.

Volanesorsen improved insulin sensitivity and glucose control in type 2 diabetes.

Top news of the day from across the health care landscape.

Sandoz to create biosimilars for 5 popular branded drugs.

Researchers examine the impact of aerobic and resistance training on cancer outcomes.

Liver cancer cells died when the AURKA-MYC interaction was inhibited.

Deficient copies of gene leaves some patients more susceptible for melanoma.

Antiretroviral therapy use and viral suppression heavily impacted by issues such as poverty and race.

Ixekizumab fully or partially cleared moderate-to-severe psoriasis in 80% of patients.

Dimethylfumarate could provide a new treatment option for several neurodegenerative diseases.

Mindfulness-based treatments may benefit patients with type 2 diabetes.

An antibody derived from the human immune system may kill cancer cells with less harm to patient.

Top news of the day from across the health care landscape.

Previous research has supported coffee consumption for reducing the risk of diseases such as cancer.

Novel agents using dill and parsley extracts show promise fighting cancer.

Ocrevus is an investigational, humanized monoclonal antibody that selectively targets CD20-positive B cells in multiple sclerosis.